199 related articles for article (PubMed ID: 2282457)
1. L-arginine and arginine analogues: effects on isolated blood vessels and cultured endothelial cells.
Schmidt HH; Baeblich SE; Zernikow BC; Klein MM; Böhme E
Br J Pharmacol; 1990 Sep; 101(1):145-51. PubMed ID: 2282457
[TBL] [Abstract][Full Text] [Related]
2. Effects of NG-substituted analogues of L-arginine on NANC relaxation of the rat anococcygeus and bovine retractor penis muscles and the bovine penile artery.
Liu XR; Gillespie JS; Gibson IF; Martin W
Br J Pharmacol; 1991 Sep; 104(1):53-8. PubMed ID: 1786518
[TBL] [Abstract][Full Text] [Related]
3. Endothelial cells metabolize NG-monomethyl-L-arginine to L-citrulline and subsequently to L-arginine.
Hecker M; Mitchell JA; Harris HJ; Katsura M; Thiemermann C; Vane JR
Biochem Biophys Res Commun; 1990 Mar; 167(3):1037-43. PubMed ID: 2322257
[TBL] [Abstract][Full Text] [Related]
4. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo.
Rees DD; Palmer RM; Schulz R; Hodson HF; Moncada S
Br J Pharmacol; 1990 Nov; 101(3):746-52. PubMed ID: 1706208
[TBL] [Abstract][Full Text] [Related]
5. The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: L-glutamine inhibits the generation of L-arginine by cultured endothelial cells.
Sessa WC; Hecker M; Mitchell JA; Vane JR
Proc Natl Acad Sci U S A; 1990 Nov; 87(21):8607-11. PubMed ID: 1978327
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the release of endothelium-derived relaxing factor in vitro and in vivo by dipeptides containing NG-nitro-L-arginine.
Thiemermann C; Mustafa M; Mester PA; Mitchell JA; Hecker M; Vane JR
Br J Pharmacol; 1991 Sep; 104(1):31-8. PubMed ID: 1786515
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory role of endothelium-derived relaxing factor in rat and human pulmonary arteries.
Crawley DE; Liu SF; Evans TW; Barnes PJ
Br J Pharmacol; 1990 Sep; 101(1):166-70. PubMed ID: 2282458
[TBL] [Abstract][Full Text] [Related]
8. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation.
Rees DD; Palmer RM; Hodson HF; Moncada S
Br J Pharmacol; 1989 Feb; 96(2):418-24. PubMed ID: 2924084
[TBL] [Abstract][Full Text] [Related]
9. L-NG-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro.
Moore PK; al-Swayeh OA; Chong NW; Evans RA; Gibson A
Br J Pharmacol; 1990 Feb; 99(2):408-12. PubMed ID: 2328404
[TBL] [Abstract][Full Text] [Related]
10. Selective production of endothelium-derived nitric oxide in canine femoral veins.
Miller VM
Am J Physiol; 1991 Sep; 261(3 Pt 2):H677-82. PubMed ID: 1679603
[TBL] [Abstract][Full Text] [Related]
11. L-arginine, but not N alpha-benzoyl-L-arginine ethyl ester, is a precursor of endothelium-derived relaxing factor.
Fasehun OA; Gross SS; Rubin LE; Jaffe EA; Griffith OW; Levi R
J Pharmacol Exp Ther; 1990 Dec; 255(3):1348-53. PubMed ID: 2175803
[TBL] [Abstract][Full Text] [Related]
12. NG-monomethyl-L-arginine and NG-nitro-L-arginine inhibit endothelium-dependent relaxations in human isolated omental arteries.
Vila J; Esplugues JV; Martinez-Cuesta MA; Martinez-Martinez MC; Aldasoro M; Flor B; Lluch S
J Pharm Pharmacol; 1991 Dec; 43(12):869-70. PubMed ID: 1687588
[TBL] [Abstract][Full Text] [Related]
13. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors.
Komas N; Lugnier C; Stoclet JC
Br J Pharmacol; 1991 Oct; 104(2):495-503. PubMed ID: 1665741
[TBL] [Abstract][Full Text] [Related]
14. Effects of guanidino compounds on the endothelium-derived relaxing factor inhibitor NG-monomethyl L-arginine.
Thomas G; Ramwell PW
J Pharmacol Exp Ther; 1991 Nov; 259(2):490-4. PubMed ID: 1719191
[TBL] [Abstract][Full Text] [Related]
15. NG-monomethyl-L-arginine paradoxically relaxes preconstricted canine intrapulmonary arteries.
Tseng CM; Goodman LW; Rubin LJ; Tod ML
J Appl Physiol (1985); 1993 Feb; 74(2):549-58. PubMed ID: 8458770
[TBL] [Abstract][Full Text] [Related]
16. Vasomotor responses of canine coronary arterial rings to NG-monomethyl-L-arginine and N omega nitro L-arginine methyl ester.
Winn MJ; Asante NK; Ku DD
J Pharmacol Exp Ther; 1993 Jan; 264(1):265-70. PubMed ID: 8423529
[TBL] [Abstract][Full Text] [Related]
17. Interaction of non-arginine compounds with the endothelium-derived relaxing factor inhibitor, NG-monomethyl L-arginine.
Thomas G; Ramwell PW
J Pharmacol Exp Ther; 1992 Feb; 260(2):676-9. PubMed ID: 1310739
[TBL] [Abstract][Full Text] [Related]
18. Reduction by NG-nitro-L-arginine of H2O2-induced endothelial cell injury.
Shimizu S; Nomoto M; Yamamoto T; Momose K
Br J Pharmacol; 1994 Oct; 113(2):564-8. PubMed ID: 7530574
[TBL] [Abstract][Full Text] [Related]
19. Modification of striatal arginine and citrulline metabolism by nitric oxide synthase inhibitors.
Ohta K; Shimazu K; Komatsumoto S; Araki N; Shibata M; Fukuuchi Y
Neuroreport; 1994 Mar; 5(7):766-8. PubMed ID: 7517194
[TBL] [Abstract][Full Text] [Related]
20. NG-nitro-L-arginine (N5-[imino(nitroamino)methyl]-L-ornithine) impairs endothelium-dependent dilations by inhibiting cytosolic nitric oxide synthesis from L-arginine.
Mülsch A; Busse R
Naunyn Schmiedebergs Arch Pharmacol; 1990; 341(1-2):143-7. PubMed ID: 2314480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
